Invention Grant
- Patent Title: Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
-
Application No.: US17176374Application Date: 2021-02-16
-
Publication No.: US11958898B2Publication Date: 2024-04-16
- Inventor: Einar Sigurdsson
- Applicant: New York University
- Applicant Address: US NY New York
- Assignee: NEW YORK UNIVERSITY
- Current Assignee: NEW YORK UNIVERSITY
- Current Assignee Address: US NY New York
- Agency: Troutman Pepper Hamilton Sanders LLP (Rochester)
- Main IPC: C07K16/18
- IPC: C07K16/18 ; A61K38/00 ; A61P25/28 ; G01N33/532

Abstract:
The present invention relates to antibody-based molecules (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to the truncated Asp421 epitope of Tau. Such antibody-based molecules are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis and/or treatment of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The antibody-based molecules of the present invention have particular utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.
Public/Granted literature
Information query